8 August 2018 - NICE has published evidence-based recommendations on the use of lenvatinib mesylate (Lenvima) and sorafenib tosylate (Nexavar) on the NHS for the treatment of adults with progressive, locally advanced or metastatic differentiated thyroid cancer who have had radioactive iodine.

Lenvatinib mesylate and sorafenib tosyklate are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hürthle cell) in adults whose disease does not respond to radioactive iodine, only if:

• they have not had a tyrosine kinase inhibitor before or
  
• they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification).
  

Lenvatinib mesylate and sorafenib tosylate are recommended only if the companies provide them according to the commercial arrangements.

Read NICE Final Appraisal Determination for lenvatinib mesylate and sorafenib tosylate